| Genzyme Corporation - SWOT Analysis company | | | | employed 11,000 people as of December 2008. The |
| profile is the essential source for top-level company | | | | company recorded revenues of $4,605 million during |
| data and information. Genzyme Corporation - SWOT | | | | the financial year (FY) ended December 2008, an |
| Analysis examines the company's key business | | | | increase of 20.8% over FY2007. The increase was |
| structure and operations, history and products, and | | | | primarily due to higher sales of Cerezyme |
| provides summary analysis of its key revenue lines | | | | ((imiglucerase for injection), Fabrazyme (agalsidase |
| and strategy. | | | | beta), Renagel (sevelamer hydrochloride), Hectorol |
| Genzyme (the company) is one of the world's leading | | | | (doxercalciferol), Thyrogen (thyrotropin alfa for |
| biotechnology companies. The company offers | | | | injection) and hematologic oncology products. The |
| medicines for, renal diseases, orthopaedics, cancer, | | | | operating profit of the company was $581.5 million |
| transplant and immune disease, and diagnostic and | | | | during FY2008, a decrease of 11.1% over FY2007. The |
| predictive testing and other rare disorders. The | | | | net profit was $421.1 million in FY2008, a decrease of |
| company primarily operates in the US and Europe. It is | | | | 12.3% over FY2007. |
| headquartered in Cambridge, Massachusetts and | | | | |